bioAffinity Technologies, Inc. (BIAF) Stock

bioAffinity Technologies, Inc. (BIAF) is a Technology stock trading at $0.53 (as of 2026-08-05), with a market capitalization of $4.28M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

bioAffinity Technologies, Inc. is a biotechnology company developing non-invasive diagnostic tests and targeted cancer therapeutics. Its CyPath lung diagnostic test is designed for early detection of lung cancer, and it conducts research into targeted cancer therapies.

Understand bioAffinity Technologies, Inc.: how it makes money

bioAffinity Technologies is developing a non-invasive lung cancer diagnostic (CyPath) and early-stage targeted cancer therapeutics, with no significant product revenue yet. The company is a pre-commercialization biotech that funds R&D through equity offerings rather than product sales.

Until CyPath generates repeatable commercial revenue, the company converts investor capital into R&D spending with no recurring income base to offset it.

Business quality (Unprofitable): Unprofitable, pre-revenue biotech; no visible path to positive operating margin in the near term.

Bull case

  • First revenue signals emerging: Revenue grew 19% year over year, suggesting initial commercial or licensing activity around CyPath. For a company founded in 2014, any revenue inflection is an early data point on whether the diagnostic is reaching clinical or commercial channels.

Bear case

  • Margin signals deep cash burn: Operating margin of -221% means the company spends more than twice its near-zero revenue to operate each quarter. The gap must be closed through dilutive equity raises, capping shareholder upside until a product actually sells.
Valuation — source: SEC EDGAR (first-party)
Price$0.53
Market Cap$4.28M
Price / Book1.14
Price / Sales0.73
FCF Yield-269.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$6.16M
Net Margin-242.0%
Return on Equity-402.9%
Debt / Equity0.07
Current Ratio1.44
Revenue Growth (YoY)19.0%
EPS Growth (YoY)276.5%
FCF Growth (YoY)23.7%
Financial Health — source: SEC EDGAR
Altman Z-Score-10.48 (distress)
Valuation vs Sector & Industry
Sector P/E (Technology)31.8
Industry P/E (Business Services)28.3
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD CAPITAL MANAGEMENT LLC ($212730.00)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryBusiness Services
CEOMaria Zannes
Employees57
CountryUS
IPO Date2022-09-01

Related Companies (Business Services; 8 comparable business services companies)

  • Absci Corporation (ABSI)
  • OmniAb, Inc. (OABI)
  • iSpecimen Inc. (ISPC)
  • OneMedNet Corporation (ONMD)
  • Biomerica, Inc. (BMRA)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • BNB Plus Corp. (BNBX)
  • 20/20 Biolabs, Inc. Common Stock (AIDX)
BIAF earnings history · BIAF institutional & insider holders · BIAF KPIs & operating metrics · BIAF financials · BIAF investor presentations & press releases · BIAF SEC filings · BIAF peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-05.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.